Key Points
- Gilead CEO Daniel Patrick O'day sold 115,640 shares on Feb. 5 at an average of $150, totaling about $17.35 million, leaving him with 613,912 shares — a 15.85% reduction in his stake.
- The Feb. 5 sale is part of a recent pattern of insider selling (including another 115,640-share sale on Jan. 23 and several 10,000-share sales in late 2023 and January 2024), signaling a notable ongoing sell-down by the CEO.
- Shares are trading near a 52-week high (~$152.50 vs. $153.13 high) with a market cap of about $189.2 billion and a P/E of ~23.6, while analysts' average target (~$136.73) and a "Moderate Buy" consensus suggest mixed market expectations.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 115,640 shares of the company's stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the sale, the chief executive officer owned 613,912 shares of the company's stock, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Daniel Patrick O'day also recently made the following trade(s):
- On Wednesday, January 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00.
- On Friday, January 23rd, Daniel Patrick O'day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00.
- On Monday, December 29th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00.
- On Friday, November 28th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total transaction of $1,265,400.00.
Gilead Sciences Price Performance
Shares of NASDAQ:GILD opened at $152.50 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a 50-day moving average price of $127.38 and a 200 day moving average price of $120.91. The company has a market cap of $189.20 billion, a P/E ratio of 23.64, a PEG ratio of 0.79 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $153.13.
Institutional Investors Weigh In On Gilead Sciences
Several institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in Gilead Sciences during the second quarter valued at $2,150,268,000. Ameriprise Financial Inc. boosted its holdings in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company's stock valued at $748,147,000 after buying an additional 5,392,191 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company's stock valued at $518,368,000 after buying an additional 4,113,999 shares during the last quarter. Invesco Ltd. grew its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company's stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Gilead Sciences by 164.4% during the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company's stock worth $387,286,000 after acquiring an additional 2,169,266 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an "overweight" rating in a report on Friday, October 31st. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Mizuho increased their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an "outperform" rating in a report on Friday, November 21st. Daiwa Securities Group boosted their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an "outperform" rating in a research report on Thursday, November 13th. Finally, Morgan Stanley cut their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $136.73.
Read Our Latest Research Report on Gilead Sciences
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
